Press release   **Stockholm, April 16, 2019**

Bactiguard's Annual Report 2018

The annual report for Bactiguard Holding AB (publ) 2018 is now available at www.bactiguard.com

The annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from May 15 and can be ordered by email to: info@bactiguard.se.

This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 08.00 CET on April 16, 2019.

For further information, please contact:
Cecilia Edström, CFO, mobile: +46 72 226 23 28

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard's coating are market leading in the USA and Japan. Bactiguard's own product portfolio of urinary catheters, central venous catheters and endotracheal tubes prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 70 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives at www.bactiguard.com